Paul Fatheree
Scientific Advisor to Small Molecule Programs

Paul has over 25 years of medicinal chemistry experience in roles of increasing leadership including positions at DiCE Molecules, Viewpoint Therapeutics, and Theravance BioPharma. He has successfully overseen the chemistry and early CMC activities for multiple research programs and has been involved in the identification of over 7 differentiated clinical candidates across multiple indications, including Vibativ® (telavancin), Velusetrag (TD-5108), Cefilavancin (TD-1792), and TD-8236, a novel, inhaled pan-JAK inhibitor.